PubMed

HIV-1 neutralization by monoclonal antibody against conserved region 2 and patterns of epitope exposure on the surface of native viruses.

Sreepian A, Permmongkol J, Kantakamalakul W, Siritantikorn S, Tanlieng N, Sutthent R.

J Immune Based Ther Vaccines. 2009 Oct 12;7:5.PMID: 19821992 [PubMed - in process]Free PMC ArticleFree textRelated citations

Conserved neutralizing epitopes of HIV type 1 CRF01_AE against primary isolates in long-term nonprogressors.

Sreepian A, Srisurapanon S, Horthongkham N, Tunsupasawasdikul S, Kaoriangudom S, Khusmith S, Sutthent R.

AIDS Res Hum Retroviruses. 2004 May;20(5):531-42.PMID: 15186528 [PubMed - indexed for MEDLINE]Related citations

Monoclonal antibodies directed against conserved epitopes on the nucleocapsid protein and the major envelope glycoprotein of equine arteritis virus.

Weiland E, Bolz S, Weiland F, Herbst W, Raamsman MJ, Rottier PJ, De Vries AA.

J Clin Microbiol. 2000 Jun;38(6):2065-75.PMID: 10834955 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins.

Patel MB, Hoffman NG, Swanstrom R.

J Virol. 2008 Jan;82(2):903-16. Epub 2007 Nov 14.PMID: 18003735 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence.

Honnen WJ, Krachmarov C, Kayman SC, Gorny MK, Zolla-Pazner S, Pinter A.

J Virol. 2007 Feb;81(3):1424-32. Epub 2006 Nov 22.PMID: 17121806 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses.

Yoshida R, Igarashi M, Ozaki H, Kishida N, Tomabechi D, Kida H, Ito K, Takada A.

PLoS Pathog. 2009 Mar;5(3):e1000350. Epub 2009 Mar 20.PMID: 19300497 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.

Pantophlet R, Aguilar-Sino RO, Wrin T, Cavacini LA, Burton DR.

Virology. 2007 Aug 1;364(2):441-53. Epub 2007 Apr 6.PMID: 17418361 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1.

Li B, Decker JM, Johnson RW, Bibollet-Ruche F, Wei X, Mulenga J, Allen S, Hunter E, Hahn BH, Shaw GM, Blackwell JL, Derdeyn CA.

J Virol. 2006 Jun;80(11):5211-8. Erratum in: J Virol. 2007 Nov;81(22):12716. PMID: 16699001 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5.

Huarte N, Lorizate M, Maeso R, Kunert R, Arranz R, Valpuesta JM, Nieva JL.

J Virol. 2008 Sep;82(18):8986-96. Epub 2008 Jul 2.PMID: 18596094 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response.

Gray ES, Moore PL, Bibollet-Ruche F, Li H, Decker JM, Meyers T, Shaw GM, Morris L.

J Virol. 2008 Mar;82(5):2367-75. Epub 2007 Dec 19.PMID: 18094155 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China.

Chong H, Hong K, Zhang C, Nie J, Song A, Kong W, Wang Y.

J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):535-43.PMID: 18209676 [PubMed - indexed for MEDLINE]Related citations

Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1.

Krachmarov CP, Honnen WJ, Kayman SC, Gorny MK, Zolla-Pazner S, Pinter A.

J Virol. 2006 Jul;80(14):7127-35.PMID: 16809318 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes.

Hioe CE, Wrin T, Seaman MS, Yu X, Wood B, Self S, Williams C, Gorny MK, Zolla-Pazner S.

PLoS One. 2010 Apr 21;5(4):e10254.PMID: 20421997 [PubMed - in process]Free PMC ArticleFree textRelated citations

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, Decker JM, Wycuff D, Harris L, Hawkins N, Wood B, Nathe C, Richman D, Tomaras GD, Bibollet-Ruche F, Robinson JE, Morris L, Shaw GM, Montefiori DC, Mascola JR.

J Virol. 2008 Dec;82(23):11651-68. Epub 2008 Sep 24.PMID: 18815292 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity.

Pantophlet R, Wrin T, Cavacini LA, Robinson JE, Burton DR.

Virology. 2008 Nov 25;381(2):251-60. Epub 2008 Sep 26.PMID: 18822440 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.

Alam SM, McAdams M, Boren D, Rak M, Scearce RM, Gao F, Camacho ZT, Gewirth D, Kelsoe G, Chen P, Haynes BF.

J Immunol. 2007 Apr 1;178(7):4424-35.PMID: 17372000 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma.

Davis KL, Bibollet-Ruche F, Li H, Decker JM, Kutsch O, Morris L, Salomon A, Pinter A, Hoxie JA, Hahn BH, Kwong PD, Shaw GM.

J Virol. 2009 Feb;83(3):1240-59. Epub 2008 Nov 19.PMID: 19019969 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B.

Gray ES, Meyers T, Gray G, Montefiori DC, Morris L.

PLoS Med. 2006 Jul;3(7):e255.PMID: 16834457 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01_AE env gene derived from HIV-1-infected patient, residing in central Thailand.

Utachee P, Jinnopat P, Isarangkura-Na-Ayuthaya P, de Silva UC, Nakamura S, Siripanyaphinyo U, Wichukchinda N, Tokunaga K, Yasunaga T, Sawanpanyalert P, Ikuta K, Auwanit W, Kameoka M.

Microbes Infect. 2009 Mar;11(3):334-43. Epub 2008 Dec 27.PMID: 19136072 [PubMed - indexed for MEDLINE]Related citations

Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.

Zolla-Pazner S, Cohen S, Pinter A, Krachmarov C, Wrin T, Wang S, Lu S.

Virology. 2009 Sep 15;392(1):82-93. Epub 2009 Jul 26.PMID: 19632700 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations